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 The specific down-regulation triggered through 
interference RNA (RNAi) provides a means to determine 
the gene functions and their contributions in an altered 
phenotype. In this way, high throughput screening (HTS) 
has emerged as a potent automated tool to study a large 
number of genes for identification of new biomarkers and 
therapeutic targets. However, the siRNA-mediated gene 
knock down requires that siRNA can reach cytoplasm 
compartment where RNAi occurs. Unfortunately, the 
siRNA is relatively vulnerable in the extracellular 
environment due to the presence of degradation enzymes 
and its high molecular weight associated to its anionic 
charge limit considerably its cell incorporation across the 
plasma membrane. Thereby, HTS requires generic 
carriers with highly efficient siRNA transfection. To 
overcome these obstacles, multifunctional nanoparticles 
comprising an imaging contrast agent are emerging as an 
original and promising approach in the improved, 
controlled and monitored delivery of siRNA. 
 
INTRODUCTION 
Small interfering RNA (siRNA) is double stranded RNA 
from 19 to 24 base pairs which induces sequence specific 
down-regulation by triggering the cleavage of a targeted 
messenger RNA (mRNA) in the cytoplasm of mammalian 
cells [1]. Since its discovery in 1998 by Fire and Melo, 
this evolutionarily conserved mechanism, called RNA 
interference (RNAi), has generated a great deal of interest 
in understanding and treating dysregulation occurring in 
pathogenesis due to selective knock-down ability of a 
gene of interest. Although siRNA is a promising nucleic 
acid tool in basic and clinical research, several barriers 
hinder its distribution to its intracellular sites of action. To 
overcome the delivery obstacles, progress has been made 
regarding the design of non-viral vectors (inorganics, 
lipids, polymers, peptides [2]) to enhance efficacy and 
specificity of the delivery. 
Among the wide range of nanocarriers, the resort to 
cationic nanostructured lipid carrier (cNLC) to form 
polyelectrolyte complex present an attractive option: (1) 
they can be designed from already approved human-use 
surfactants and inexpensive natural ingredients; (2) they 
can be manufactured by solvent-free up-scalable 
techniques; (3) their lipid core constitutes an ideal 
reservoir for the high loading of hydrophobic molecules 
(drugs, fluorophores) [3]; (4) Specific targeting by 
grafting antibodies on the shell is possible.  
In our study, proof of concept is performed by 
formulating nanoemulsion droplets with 1,2-dioleoyl-sn-
glycrol-3-trimethylammonium-propane (DOTAP) as a 
cationic emulsifier to promote complexation with siRNA. 
The efficient and active transfection of lipid 
nanocarriers/siRNA complexes is demonstrated. 
 
EXPERIMENTAL METHODS 
Cationic lipid nanoparticles are prepared by emulsion 
templating through ultrasonication based on a process 
described by Delmas et al [4] [5]. Both aqueous and lipid 
phase contain a blend of solid (Suppocire NCTM) and 
liquid (Super refined Soybean oil) glycerides with 
phospholipids (Lipoid S75-3TM) and DOTAP, while the 
aqueous phase is composed of PEG surfactant (Myrj 
52TM) dissolved in 154mM NaCl aqueous buffer. 80 µL of 
a 10 mM lipophilic cyanine derivatives solution (DiD) are 
eventually poured in oil premix to allow dye-labelling of 
the lipid nanocarrier and solvent is evaporated under 
vacuum. The amounts of the various constituents were 
determined according to a Design Of Experiment (DOE) 
to isolate compositions allowing stable and effective 
siRNA transfection. After homogenization at high 
temperature, both phases are crudely mixed. Then, 
sonication cycles are performed during a 10 min period 
(VCX750 Ultrasonic processor, 3 mm probe, Sonics, 
France; sonication power 20%). Non encapsulated 
components are separated from nanoparticle dispersions 
by gentle dialysis overnight in 154 mM NaCl against 
1,000 times their volume (MWCO: 12,000 Da, 
ZelluTrans). Before use, nanoparticle dispersions are 
filtered through 0.22 µm cellulosic membrane (Millipore).  
PC3 prostatic cells are seeded in 96-well plates. After 24 
hour incubation at 37°C, different concentrations of lipid 
nanoparticles, from 1 to 500 µg/mL, are added to the 
culture medium for 24 hours. Cytotoxicity is assessed 24 
hours following the nanoparticle removal using the WST-
1 assay (soluble formazan derivative reagent). WST-1 
reagent (Roche) is added (10%) to the culture medium 
and kept in the incubator for 3 hours. Cells without 
nanoparticles and cells incubated with a solution of H2O2 
10 mM are respectively used as negative and positive 
controls. Absorbance is then recorded at 450 nm (soluble 
formazan titration) and 690 nm (background substraction) 
using a microplate reader (Tecan).  
To study transfection efficiency, PC3 prostatic cells are 
seeded overnight at 37°C. They are incubated for 1 hour 
at 37°C in the presence of lipid nanoparticles 
encapsulating DiD at a concentration of 0.61µM DiD and 
125 µg/mL of total lipids complexed with Alexa488-
siRNA (20 nM). They are subsequently rinsed with PBS 
and fixed with paraformaldehyde 1%. Nuclei are labeled 
with DAPI for fluorescence microscopy or treated by flow 
cytometry (FACS LSR2, Becton Dickinson, France). 
To validate the down-regulation efficacy, PC3 prostatic 
cells overexpressing Green Fluorescent Protein (GFP) are 
developped. Chemically synthetized GFP siRNA is used 
to down-regulate GFP expression. Cells are seeded 24 h 
prior to experiments. Lipid nanoparticles/siRNA 
complexes containing typically 0.65 µg (100 nM) siRNA 
are added to each well and cells are allowed to grow 
further for 72 h. Lipid nanoemulsion/siRNA complexes 
formulated in the same conditions but with siRNA which 
has no homology to any known mammalian gene instead 
of siGFP are used as negative control. Cells are analyzed 
by flow cytometry and imaged by videomicroscopy. 
 
RESULTS AND DISCUSSION 
Toxicity induced by cationic lipid nanoemulsions is 
studied on prostate cells. The studied particles present an 
IC50 higher than 500 µg/mL (Fig.1.) which demonstrates a 
good tolerance. For these cationic nanoparticles, 
concentration of approximatively 10 µg/mL is used in 
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Fig.1.: Toxicity assay with cationic lipid nanoparticles on 
protate cells PC3. 
 
To study transfection efficiency, internalization of both 
DiD-entrapping nanoparticles and Alexa 488-labelled 
siRNA is vizualised by fluorescence and analyzed by flow 
cytometry (Fig.2.). After only 30’, 96.8% of cells are 
positives for siRNA (FITC) and nanoparticles (APC). 
After 3h, all cells are positive for the complexes. 
Relevant lipid nanoparticles formulations are selected to 
transfection test with GFP siRNA to down-regulate the  
 
      
 
Fig.2.: FACS analysis of PC3 cells before after incubation 
of complexes cationic lipid nanoparticles/siRNA 
overtime. 
 
GFP expression. FACS analysis reveal that lipid 
nanoparticle-based complexes may induce a significant 
inhibition of the targeted GFP expression (around 75%), 
demonstrating thus a relatively efficient transfection. This 
efficiency is visualized with videomicroscopy where GFP 
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Fig.3.: Epifluorescence imaging of prostatic cells 
overexpressing GFP protein (T0) after internalization of 
cationic Lipidot/siRNA complex (7h) and after specific 
down-regulation of GFP protein by siRNA (26h). 
 
CONCLUSION 
Cationic lipid nanoemulsions developed in our laboratory 
constitute a promising approach to transfect siRNA and 
down-regulate gene expression. Actually, cationic 
nanoparticles present high colloidal stability and 
transfection efficiency without inducing cytotoxicity. First 
results have also demonstrated improved transfection on 
primary cells compared to commercially available 
lipoplexes. Next steps will include the improvement of 
transfection efficiency and the surface functionalization of 
particles with specific ligand in order to target cells hard 
to transfect using commercially available agents. 
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